Literature DB >> 7040265

Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice.

C J Bailey, P R Flatt, T W Atkins.   

Abstract

Expression of the obese hyperglycaemic (bo/ob) syndrome in mice is modified by the background genome. The Aston colony carries the ob gene on a mixed background which produces a unique combination of different features shown by ob/ob mice on other backgrounds. The maximum body weight of Aston ob/ob mice exceeded that of other colonies, possibly reflecting a trait for higher growth rate in the background genome. The hyperphagia, marked hyperinsulinaemia and moderate hyperglycaemia observed during the development of the syndrome receded in old mice. Plasma glucagon concentrations in the fed state were similar to +/+ mice and did nor Vary throughout life. Hyperplasia of the B-cells increased inordinately during the development of the syndrome, but declined in older mice coincident with progressive intercellular vacuolation and the appearance of acinar-like cells within the islets. A-cell hyperplasia was greater in young mice, and A-cells became relocated throughout the islets of older mice. The distinct pattern of age-related changes in ob/ob mice indicates that experiments using this gene type should define clearly their age as well as genetic background.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7040265

Source DB:  PubMed          Journal:  Int J Obes


  12 in total

1.  Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice.

Authors:  A M McKillop; B M Moran; Y H A Abdel-Wahab; P R Flatt
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

2.  Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

Authors:  N Irwin; P L McClean; F P M O'Harte; V A Gault; P Harriott; P R Flatt
Journal:  Diabetologia       Date:  2007-05-08       Impact factor: 10.122

3.  Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes.

Authors:  N Irwin; P Frizelle; I A Montgomery; R C Moffett; F P M O'Harte; P R Flatt
Journal:  Diabetologia       Date:  2012-07-20       Impact factor: 10.122

4.  Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.

Authors:  V A Gault; F P M O'Harte; P Harriott; M H Mooney; B D Green; P R Flatt
Journal:  Diabetologia       Date:  2003-02-12       Impact factor: 10.122

5.  Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice.

Authors:  P R Flatt; C J Bailey
Journal:  Diabetologia       Date:  1981-05       Impact factor: 10.122

6.  Increased responsiveness to glucoregulatory effect of opiates in obese-diabetic ob/ob mice.

Authors:  C J Bailey; P R Flatt
Journal:  Diabetologia       Date:  1987-01       Impact factor: 10.122

7.  Insulin-like effect of pinitol.

Authors:  S H Bates; R B Jones; C J Bailey
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

8.  Evaluation of traditional plant treatments for diabetes: studies in streptozotocin diabetic mice.

Authors:  S K Swanston-Flatt; C Day; C J Bailey; P R Flatt
Journal:  Acta Diabetol Lat       Date:  1989 Jan-Mar

9.  A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.

Authors:  Victor A Gault; Vikas K Bhat; Nigel Irwin; Peter R Flatt
Journal:  J Biol Chem       Date:  2013-10-28       Impact factor: 5.157

10.  Effect of metformin on hepatocyte insulin receptor binding in normal, streptozotocin diabetic and genetically obese diabetic (ob/ob) mice.

Authors:  J M Lord; T W Atkins; C J Bailey
Journal:  Diabetologia       Date:  1983-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.